Lab Test Data and Fill Weight
What has been measured, by which laboratory, on what date, and against what label. Including where no test exists. This page is a record of testing, not a claim about it.
What a usable lab report has to contain
Why fill weight, and not purity
Purity is close to universal in this category. Reports across the market cluster near the top of the scale, which makes it a poor way to tell suppliers apart. Content weight does not cluster. Published third-party data across the wider market includes results at 44.8 percent under label and 35.4 percent under label, and one lot returning 13.07mg in one vial and 9.47mg in another from the same batch.
That is the measurement worth publishing, and it is the one almost nobody does.
Reports on file
Every laboratory report currently held for material in the Etched Research supply chain. Measured content is compared to the labeled amount. A blank means no report exists, not that a test was passed.
| Compound | Measured vs label | Purity | Laboratory | Date |
|---|---|---|---|---|
| BPC-157 10mg | 10.58mg / +5.8% | 99.734% | Janoshik Analytical | April 2026 |
| BPC-157 10mg | 11.39mg / +13.9% | 99.155% | Janoshik Analytical | May 2026 |
| TB-500 10mg | 11.59mg / 11.48mg | 99.605% / 99.512% | Janoshik Analytical | November 2025 |
| TB-500 10mg | 12.07mg / +20.7% | 99.234% | Janoshik Analytical | May 2026 |
| MOTS-c 10mg | 10.74mg / 10.96mg | 99.278% / 99.706% | Janoshik Analytical | November 2025 |
| SS-31 10mg | 10.69mg / 10.61mg | 99.811% / 99.861% | Janoshik Analytical | November 2025 |
| KPV 10mg | 10.47mg / 10.36mg | 99.689% / 99.582% | Janoshik Analytical | November 2025 |
| GHK-Cu 100mg | 98.26mg / 102.54mg | 99.868% / 99.756% | Janoshik Analytical | November 2025 |
| Retatrutide 10mg | 10.61mg / 10.37mg | 99.419% / 99.477% | Janoshik Analytical | October 2025 |
| Retatrutide 30mg | 30.61mg / 29.11mg | 99.393% / 99.764% | Janoshik Analytical | October 2025 |
| Retatrutide 30mg | 32.79mg / +9.3% | 99.777% | Janoshik Analytical | May 2026 |
| Tirzepatide 30mg | 29.55mg / -1.5% | 99.903% | Janoshik Analytical | May 2026 |
| NAD+ 500mg | 496.78mg / -0.6% | not requested | Janoshik Analytical | April 2026 |
| BPC-157 (in BPC-157 + TB-500 Blend 20mg) | 12.68mg / +26.8% | not requested | Janoshik Analytical | June 2026 |
| TB-500 (in BPC-157 + TB-500 Blend 20mg) | 11.42mg / +14.2% | not requested | Janoshik Analytical | June 2026 |
| BPC-157 (in a 10mg BPC-157 + TB-500 blend vial, not in the shop) | 6.24mg / +24.8% | not requested | Janoshik Analytical | July 2026 |
| TB-500 (in a 10mg BPC-157 + TB-500 blend vial, not in the shop) | 6.18mg / +23.6% | not requested | Janoshik Analytical | July 2026 |
| BPC-157 (in GLOW 70mg) | 11.69mg / +16.9% | not requested | Janoshik Analytical | August 2026 |
| TB-500 (in GLOW 70mg) | 11.24mg / +12.4% | not requested | Janoshik Analytical | August 2026 |
| GHK-Cu (in GLOW 70mg) | 56.76mg / see note | not requested | Janoshik Analytical | August 2026 |
| Tesamorelin 10mg | 10.38mg / +3.8% | 99.043% | Janoshik Analytical | November 2025 |
| Semax 10mg | 12.55mg / +25.5% | 99.905% | Janoshik Analytical | May 2026 |
| Thymosin Alpha-1 10mg | 12.31mg / +23.1% | 99.901% | Janoshik Analytical | May 2026 |
| GHK-Cu 50mg | 53.02mg / see note | 99.875% | Janoshik Analytical | August 2026 |
| Selank 10mg | 12.49mg / +24.9% | 99.955% | Janoshik Analytical | August 2026 |
| PT-141 10mg | 10.68mg / +6.8% | 99.847% | Janoshik Analytical | August 2026 |
| Epithalon | no report on file | — | — | — |
| Ipamorelin | no report on file | — | — | — |
| 5-Amino-1MQ | no report on file | — | — | — |
| ARA-290 | no report on file | — | — | — |
| Cagrilintide | no report on file | — | — | — |
| IGF-1 LR3 | no report on file | — | — | — |
| KLOW | no report on file | — | — | — |
| MOTS-c 40mg | no report on file | — | — | — |
Compound names above link to their product pages. See the full catalog.
Four things this page is not
Notes on the data
- BPC-157 10mg, TB-500 10mg and Retatrutide 30mg each carry more than one dated report, from the same lab on the same compound. Two dated results is a stronger signal than one, since it shows the same lab checking the same compound over time rather than a single point-in-time snapshot.
- The GHK-Cu figure in GLOW is unresolved. The report shows 56.76mg of copper complex containing 50.02mg GHK. Whether the 50mg label refers to the complex or to GHK content changes the result from roughly +13.5% to roughly +0.04%. It is listed as unresolved rather than reported as either.
- The GHK-Cu 50mg figure is unresolved the same way. The report shows 53.02mg of copper complex containing 44.77mg GHK. Against the 50mg label that is roughly +6.0% if the label refers to the complex, and roughly -10.5% if it refers to GHK content.
- GHK-Cu 50mg, Selank and PT-141 were tested in August 2026 on material submitted by current suppliers. The GHK-Cu report names a supplier batch that has not yet been matched to a lot Etched holds. The Selank and PT-141 reports name no batch.
- Purity was not requested on three of the original four supplier-blend reports (the BPC-157 + TB-500 blend and GLOW rows above). One states it directly in its scope: identity and amount, purity not included. That is a gap in what was ordered, not a failed test.
- Report documents are not posted. Each one names its manufacturer on the face of the page. Etched Research does not publish supplier identity, so the measurements are reproduced here rather than the documents.
What happens next
Lot identifiers will be assigned to inventory on arrival. Material from those lots will then be submitted for independent analysis, and the results will post to this page against the lot number, so a report can be matched to a vial. Laboratories under evaluation for that work include Janoshik Analytical and Freedom Diagnostics, selected against the four criteria at the top of this page rather than by name.
Until a lot has been tested under Etched Research, this page shows what the supply chain has measured and nothing further.
For research use only. Not for human consumption. Nothing on this page is a claim about any compound’s effect, safety, or suitability for any purpose.